Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT06613360 is registered in ClinicalTrials.gov with Cullinan Therapeutics Inc. as lead sponsor.

NCT NCT06613360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06613360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Lead sponsor
Cullinan Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 21, 2025
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sle, sle (systemic lupus)